MedAdvisor and Sigma sign two-year agreement

MedAdvisor and Sigma Healthcare have signed a two-year agreement that will see MedAdvisor provide custom branded versions of the mobile app for promotion and use by a number of Sigma brands.

To date MedAdvisor is already the partner of choice for more than 400 Sigma pharmacy franchise partners. This new agreement will also create the opportunity to add about 200 incremental pharmacies into MedAdvisor’s network.

Following this agreement, MedAdvisor has formalised partnerships through signed group agreements with TerryWhite Chemmart, Chemist Warehouse and Sigma Healthcare franchise partners. These groups collectively represent about 26 per cent of the total pharmacy market.

“Sigma has been a long-term shareholder and supporter of the business and we’re really pleased to formally document this agreement to help better support their 600-plus pharmacies, particularly as the market shifts with ePrescribing,” MedAdvisor CEO Robert Read said.

MedAdvisor has continued to innovate products for the Australian market, some of which are to build improvements in efficiency and workflow for pharmacies while building tighter connections with patients.

Sigma Healthcare Executive General Manager for Retail Pharmacy Jeff Sells said: “At Sigma we’re committed to providing our pharmacy franchise partners with market leading solutions across the retail and digital technology space, allowing them to maximise time with patients and build better businesses.

“MedAdvisor continues to innovate and lead the market in both the patient app experience and pharmacy medication management software. We’re pleased to be able to partner with MedAdvisor to further support electronic prescription readiness as we transition to an ePrescribing environment.”

Sigma Healthcare owns Amcal, Guardian, Discount Drug Stores, PharmaSave, WholeLife and Chemist King, which represent more than 600 pharmacies around Australia.

Must Read

First steps towards national screening for Barrett’s oesophagus

0
New research is exploring low-cost, non-invasive ways to diagnose Barrett’s oesophagus, a condition associated with deadly oesophageal cancer, to find effective strategies to identify...